Approximately 4,500 women with uterine fibroids will be eligible for new oral treatment after the National Health Technology Assessment Organization (NICE) recommends Lergolix containing estradiol and norethisterone acetate (Ryeqo) in the final draft guidance.
Treatment options for uterine fibroid symptoms include hormonal contraceptives and nonsteroidal anti-inflammatory drugs (NSAIDs). However, injectable gonadotropin-releasing hormone (GnRH) agonists are often used before surgical options to treat moderate to severe symptoms.
Take once daily as a tablet containing 40 mg of relgolix, 1 mg of estradiol, 0.5 mg of norethisterone acetate This is another treatment option for women with moderate to severe symptoms, of estrogen and progesterone. The ovaries work by reducing the release of hormones that control production.
Lergolix, including estradiol and norethisterone acetate, provides an effective alternative to surgical and injectable GnRH agonists, which also serves to reduce the production of estrogen and progesterone in the ovaries. Lergolix, which contains estradiol and norethisterone acetate for the treatment of uterine fibroids, will be available three months after the final guidance is published.
Helen Knight, Interim Director of Drug Evaluation at the NICE Center for Health Technology Evaluation, Said: “Uterine fibroids can have a significant impact on quality of life. In addition to many debilitating symptoms, there is a real lack of long-term options.
“This treatment has the potential to improve quality of life. It is more convenient than injection treatment in the hospital because it not only effectively relieves symptoms, but can also be taken at home.
“It can also be used for a long time. This means that symptom relief is improved and lasting. It is well tolerated and thousands of women avoid invasive surgery that is always at risk. It means you can do it. “
Maria Colefield, Minister of Women’s Health, said:: “Approximately one in three women can suffer from uterine fibroids at some point in their lives. Symptoms can seriously affect a woman’s health and can lead to infertility if left untreated.
“Therefore, this is another breakthrough to improve women’s quality of life and alleviate symptoms, as well as increase available drug choices and provide alternative minimally invasive treatment options. It is a typical step.
“I am working to close gender health inequalities so that women can lead healthier and happier lives, and later this year, the first women to address these inequalities. We will announce our health strategy. “
NICE Guidance for Treating Symptoms of Uterine Fibroids
Source link NICE Guidance for Treating Symptoms of Uterine Fibroids